Get the Stockscreener App
3.94
2.34%
0.09
After Hours:
3.94
Protara Therapeutics Inc stock is traded at $3.94, with a volume of 1.30M.
It is up +2.34% in the last 24 hours and down -14.35% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$3.85
Open:
$3.9
24h Volume:
1.30M
Relative Volume:
4.56
Market Cap:
$153.32M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.3972
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
-5.52%
1M Performance:
-14.35%
6M Performance:
+106.28%
1Y Performance:
+29.18%
1-Day Range:
$3.78
$4.07
1-Week Range:
$3.78
$4.3784
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.94 | 153.32M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
Protara Therapeutics Announces Appointment of Leonardo Viana Nic - GuruFocus
Scotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform Recommendation - Nasdaq
Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target - marketscreener.com
Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News - GuruFocus
Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News - GuruFocus
Protara Therapeutics Names Leonardo Viana Nicacio CMO - MarketScreener
Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - The Manila Times
Strategic Leadership Boost: Protara Gains 20-Year Oncology Expert as CMO Ahead of Key Trial Data - Stock Titan
Could Protara's ADVANCED-2 Trial Data Trigger A Stock Rally? - RTTNews
Protara Therapeutics to Present Interim Analysis from the Phase - GuruFocus
Commonwealth Equity Services LLC Has $195,000 Stock Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada
Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade - MSN
Protara to present bladder cancer trial data at AUA meeting - Investing.com Australia
Protara Therapeutics to Present Interim Analysis from the - GlobeNewswire
Critical Phase 2 Data Coming: TARA-002 Shows Promise in Treating Resistant Bladder Cancer - Stock Titan
Cantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight Recommendation - MSN
Protara Therapeutics officer sells shares worth $96,144 By Investing.com - Investing.com Australia
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (TARA) - Seeking Alpha
Protara Therapeutics officer sells shares worth $96,144 - Investing.com India
Cantor Fitzgerald Brokers Lower Earnings Estimates for TARA - Defense World
Cantor Fitzgerald Predicts TARA FY2025 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Protara reveals choline deficiency in parenteral support patients By Investing.com - Investing.com South Africa
Protara reveals choline deficiency in parenteral support patients - Investing.com
Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - GlobeNewswire
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Cantor Fitzgerald - Defense World
Cantor Fitzgerald sets Overweight rating on Protara stock - Investing.com India
Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
Protara Therapeutics shares rise on narrower Q4 loss By Investing.com - Investing.com South Africa
Protara Therapeutics shares rise on narrower Q4 loss - Investing.com
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):